新冠肺炎击垮全球航空业 英国廉航Flybe先破产倒下！
https://www.youtube.com/watch?v=rhD1gKakCgw

卫星发现永暑礁上大批战机，美奉劝越南放弃，一旦开战必全军覆没
https://www.youtube.com/watch?v=YqoYUbUTNqU

黑天鹅又灰犀牛

9-3-2020
WTI future USD 30

9-3-2020
WTI future USD 30

Oil drops 2% as steeper OPEC+ output cuts not yet agreed
LONDON (March 6): Oil prices slid 2% on Friday on concerns that Russia may not agree to a steeper OPEC+ output cut to support prices and on the spectre of a prolonged economic slowdown due to the coronavirus outbreak.

Brent crude was down US$1.20, or 2.4%, at US$48.79 per barrel by 0954 GMT, while US West Texas Intermediate (WTI) was US$1, or 2.1%, lower at US$44.90 per barrel.

The Organization of the Petroleum Exporting Countries (OPEC) was holding crunch talks with its allies on Friday after the group told Russia and others it favoured an additional 1.5 million barrels per day (bpd) of oil cuts until the end of 2020.

The new deal would mean supply curbs by OPEC and its allies, a grouping known as OPEC+, amounting to a total of 3.6 million bpd, or about 3.6% of global supplies.

Non-OPEC states were expected to contribute 500,000 bpd to the overall extra cut, OPEC ministers said. But Russia and Kazakhstan, both members of OPEC+, said they had not yet agreed to the deeper cut, raising the risk of a collapse in cooperation that has propped up crude prices since 2016.

Some analysts expected Moscow to ultimately endorse the agreement.

"If it says no, the entire union could collapse — and with it any new bilateral trade and investment deals in the pipeline as well as the strategic influence Moscow has secured by participating in the production agreement," RBC Capital Markets said in a research note.

"There will be a flurry of high level calls between Moscow, Riyadh and Abu Dhabi to get the deal done."

Concerns about the economic environment are overwhelming the positive impact of the proposed big output cuts, said Michael McCarthy, chief market strategist at CMC Markets.

Global stock markets tumbled on Friday as disruptions to business from the spreading coronavirus epidemic worsened. European shares opened sharply lower, with travel stocks bearing the brunt.

However, after marking its worst weekly performance since the 2008 financial crisis a week ago, the MSCI All-Country World Index was up 1.7% this week.

Even with the deeper cut, Goldman Sachs said the OPEC+ deal will not prevent a global oil market surplus in the second quarter. The bank maintained its Brent price forecast at US$45 a barrel in April.

"Ultimately a rebound in demand, not supply cuts, will be the necessary catalyst for a sustainable rebound in prices," the bank said.

Meanwhile ANZ said global oil consumption could fall by 1.6 million bpd in the first half of 2020 and contract by around 300,000 bpd for the full year.

"Growth may return in H2 (second half of 2020), but is unlikely to be enough to offset the losses," the bank said.

"(I) expect that it is just not OPEC and Russia looking to stabilise prices but also the US producers," said Jonathan Barratt, chief investment officer at Probis Group.

投资石油天然气公司要小心
https://klse.i3investor.com/blogs/tombthieve/231051.jsp

投资石油天然气公司要小心
https://klse.i3investor.com/blogs/tombthieve/231051.jsp

投资石油天然气公司要小心
https://klse.i3investor.com/blogs/tombthieve/231051.jsp

投资石油天然气公司要小心
https://klse.i3investor.com/blogs/tombthieve/231051.jsp

投资石油天然气公司要小心
https://klse.i3investor.com/blogs/tombthieve/231051.jsp

投资石油天然气公司要小心
https://klse.i3investor.com/blogs/tombthieve/231051.jsp

投资石油天然气公司要小心
https://klse.i3investor.com/blogs/tombthieve/231051.jsp

投资石油天然气公司要小心
https://klse.i3investor.com/blogs/tombthieve/231051.jsp

北大方正被疫情推向破產？
https://www.youtube.com/watch?v=uo99oJvgUJA

PUC Berhad (“PUC”) was incorporated in Malaysia on 3 November, 1997 by China Founder Group. It was listed on the ACE Market of Bursa Malaysia Securities Berhad on 8 April, 2002. Throughout the years, PUC and its subsidiaries have built a solid foundation in integrated media services and payment solutions. In mid-2007, the Group embarked on a digital business journey. Today, the Group’s digital services include financial technology related services, new media, eCommerce, mobile payment, digital imaging, and artificial intelligence. These continuous efforts are in line with the Group’s vision to be a world-class homegrown digital lifestyle service provider.
https://www.puc.com/wp-content/uploads/2019/12/PUC-Berhad_Group-Corpor...

geary are you study science in school?
science student and professor all know virus don't have any medicine ,want recover clear virus need antibody and immune system .
why all scientists no come out explanation what is virus ?
they also know government comment about medicine to stable society let people not too scary and panic .

tourism hit hard need rebound need two year...airasia will downward at least one year

outbreak corona virus from Jan ...manufacture mask limited production catalyst for short term play one to three month only trend cannot continue high shares prices cannot maintain will retrace...better invest NFCP and 5G related stock longer trend Megatrend will move and growth atleast until 2030 years

outbreak corona virus from Jan ...manufacture mask limited production catalyst for short term play one to three month only trend cannot continue high shares prices cannot maintain will retrace...better invest NFCP and 5G related stock longer trend Megatrend will move and growth atleast until 2030 years

when SARS airasia also difficult business drop shares price drop to 75cent

AAX
6.35 billion debt
cash flow 400 m
financial losses
2019 : -366m
2018: -241 m

6.35 billion debt
cash flow 400 m
financial losses
2019 : -366m
2018: -241 m

15.97 billion shares issued too much is most flood stock in bursa
no longer will shares consolidated 10:1

開門就賠20億！北京賓士緊急發函官方求復工 陸停產韓日法車廠跟進？特斯拉市值竟超福特通用？-
https://www.youtube.com/watch?v=TETx-0qjii4

New coronavirus vaccine may be faster to develop
KUALA LUMPUR (Feb 12): With the number of cases and deaths already surpassing that of SARS, teams around the world are racing to come up with a vaccine against the novel coronavirus (Covid-19).
At the time of writing, the virus has infected 45,194 people and killed 1,114 others.
Developing a vaccine safe for human use typically takes years, but there is reason to believe that the process will be speedier this time around, said academician and virologist Emeritus Prof Datuk Dr Lam Sai Kit.
“Advances in technology now makes it possible to come up with candidate vaccines in a matter of weeks, unlike traditional methods which can take years,” he told Bernama when contacted.
In addition to that, scientists in China sequenced the virus’s genome and made it available on Jan 10, just a month after the Dec 8 report of the first case of pneumonia from an unknown virus in Wuhan.
In contrast, scientists took more than half a year to sequence the SARS coronavirus after the outbreak began in late 2002.

How long will it take?
Lam noted that although candidate vaccines may be available in a matter of weeks, it would take much longer for them to be evaluated for human use.
“These candidate vaccines have to be tested in animal studies before human clinical trials can be started. It is still a long road ahead, and by the time a vaccine is ready, the outbreak may already be over — like in the case of SARS, where it took 20 months before a candidate vaccine was developed,” said Lam.
The vaccine never made it to the market because the virus was successfully contained with public health measures. The vaccine against MERS, meanwhile, is still being developed.
Immunologist Datuk Dr Musa Nordin said despite the pressure to come up with a vaccine as soon as possible, it must be noted that vaccine development remains an expensive and risky process.
“On average, it takes 10 years from pre-clinical trials through Phase 1-3 clinical trials before it is proven efficacious and safe for registration by regulatory bodies and use in man.
“However, the Covid-19 has the benefit of experience with previous candidate vaccines for MERS and SARS, allowing a jump start on the development of vaccines. If I had to hazard a best optimistic guess, I would say (a Covid-19 vaccine would be developed) within six months,” he said to Bernama.

What if it mutates?
One of the fears is that the Covid-19 would mutate after a vaccine is finally developed, affecting its efficacy.
However, it should be noted that Covid-19 does not undergo the same type of genome shuffling as the influenza virus, which is constantly mutating.
Like SARS, the genome of the Covid-19 comprises a single strand of RNA (ribonucleic acid). Microbes with such genome are known to mutate very quickly, but SARS has a molecular proofreading system that reduces its mutation rate.
Given the similarity to SARS at the genomic level, it has been suggested that the Covid-19 would not be as prone to mutation as the flu virus, which comprises multiple single-stranded RNA segments.
Therefore, if a vaccine is produced, it would still be effective.
Lam said that mutation is always a possibility with RNA viruses like the Covid-19.
“Usually, a major change happens when the virus jumps species. Hopefully, if there is a mutation, it will be a minor and not involving the spike protein, which is the important antigen used to produce the neutralising antibody in our immune system.
“With minor changes, the vaccine will still offer protection, or modify the severity of the disease,” he said.
CEPI
The Coalition of Endemic Preparedness Innovations (CEPI) in January announced that it would be funding three programmes to develop vaccines against the 2019-nCov.
It has engaged, among others, the Queensland University to work on a vaccine using its recently developed rapid response technology.
The university’s head of School of Chemistry and Molecular Biosciences Prof Paul Young said that they would be using the novel technology, known as the molecular clamp, for the rapid generation of the vaccine.
Young’s team of researchers have already experienced using this novel technology to produce candidate vaccines against influenza, Nipah, Ebola, and MERS. The team is optimistic that it will be able to develop the Covid-19 vaccine within six months.
“We are working around the clock to produce enough of the spike proteins in cells to produce this sub-unit vaccine,” said Young in an email.
A sub-unit vaccine is a fragment of a pathogen, typically a surface protein that is used to trigger an immune response. This in turn will stimulate acquired immunity against the pathogen from which it is derived.
CEPI is a non-profit organisation formed in 2017 to fund vaccine development for emerging infectious diseases. It is based in Oslo, Norway, and is a global partnership created to spearhead development

New coronavirus vaccine may be faster to develop
KUALA LUMPUR (Feb 12): With the number of cases and deaths already surpassing that of SARS, teams around the world are racing to come up with a vaccine against the novel coronavirus (Covid-19).
At the time of writing, the virus has infected 45,194 people and killed 1,114 others.
Developing a vaccine safe for human use typically takes years, but there is reason to believe that the process will be speedier this time around, said academician and virologist Emeritus Prof Datuk Dr Lam Sai Kit.
“Advances in technology now makes it possible to come up with candidate vaccines in a matter of weeks, unlike traditional methods which can take years,” he told Bernama when contacted.
In addition to that, scientists in China sequenced the virus’s genome and made it available on Jan 10, just a month after the Dec 8 report of the first case of pneumonia from an unknown virus in Wuhan.
In contrast, scientists took more than half a year to sequence the SARS coronavirus after the outbreak began in late 2002.

How long will it take?
Lam noted that although candidate vaccines may be available in a matter of weeks, it would take much longer for them to be evaluated for human use.
“These candidate vaccines have to be tested in animal studies before human clinical trials can be started. It is still a long road ahead, and by the time a vaccine is ready, the outbreak may already be over — like in the case of SARS, where it took 20 months before a candidate vaccine was developed,” said Lam.
The vaccine never made it to the market because the virus was successfully contained with public health measures. The vaccine against MERS, meanwhile, is still being developed.
Immunologist Datuk Dr Musa Nordin said despite the pressure to come up with a vaccine as soon as possible, it must be noted that vaccine development remains an expensive and risky process.
“On average, it takes 10 years from pre-clinical trials through Phase 1-3 clinical trials before it is proven efficacious and safe for registration by regulatory bodies and use in man.
“However, the Covid-19 has the benefit of experience with previous candidate vaccines for MERS and SARS, allowing a jump start on the development of vaccines. If I had to hazard a best optimistic guess, I would say (a Covid-19 vaccine would be developed) within six months,” he said to Bernama.

What if it mutates?
One of the fears is that the Covid-19 would mutate after a vaccine is finally developed, affecting its efficacy.
However, it should be noted that Covid-19 does not undergo the same type of genome shuffling as the influenza virus, which is constantly mutating.
Like SARS, the genome of the Covid-19 comprises a single strand of RNA (ribonucleic acid). Microbes with such genome are known to mutate very quickly, but SARS has a molecular proofreading system that reduces its mutation rate.
Given the similarity to SARS at the genomic level, it has been suggested that the Covid-19 would not be as prone to mutation as the flu virus, which comprises multiple single-stranded RNA segments.
Therefore, if a vaccine is produced, it would still be effective.
Lam said that mutation is always a possibility with RNA viruses like the Covid-19.
“Usually, a major change happens when the virus jumps species. Hopefully, if there is a mutation, it will be a minor and not involving the spike protein, which is the important antigen used to produce the neutralising antibody in our immune system.
“With minor changes, the vaccine will still offer protection, or modify the severity of the disease,” he said.
CEPI
The Coalition of Endemic Preparedness Innovations (CEPI) in January announced that it would be funding three programmes to develop vaccines against the 2019-nCov.
It has engaged, among others, the Queensland University to work on a vaccine using its recently developed rapid response technology.
The university’s head of School of Chemistry and Molecular Biosciences Prof Paul Young said that they would be using the novel technology, known as the molecular clamp, for the rapid generation of the vaccine.
Young’s team of researchers have already experienced using this novel technology to produce candidate vaccines against influenza, Nipah, Ebola, and MERS. The team is optimistic that it will be able to develop the Covid-19 vaccine within six months.
“We are working around the clock to produce enough of the spike proteins in cells to produce this sub-unit vaccine,” said Young in an email.
A sub-unit vaccine is a fragment of a pathogen, typically a surface protein that is used to trigger an immune response. This in turn will stimulate acquired immunity against the pathogen from which it is derived.
CEPI is a non-profit organisation formed in 2017 to fund vaccine development for emerging infectious diseases. It is based in Oslo, Norway, and is a global partnership created to spearhead development

New coronavirus vaccine may be faster to develop
KUALA LUMPUR (Feb 12): With the number of cases and deaths already surpassing that of SARS, teams around the world are racing to come up with a vaccine against the novel coronavirus (Covid-19).
At the time of writing, the virus has infected 45,194 people and killed 1,114 others.
Developing a vaccine safe for human use typically takes years, but there is reason to believe that the process will be speedier this time around, said academician and virologist Emeritus Prof Datuk Dr Lam Sai Kit.
“Advances in technology now makes it possible to come up with candidate vaccines in a matter of weeks, unlike traditional methods which can take years,” he told Bernama when contacted.
In addition to that, scientists in China sequenced the virus’s genome and made it available on Jan 10, just a month after the Dec 8 report of the first case of pneumonia from an unknown virus in Wuhan.
In contrast, scientists took more than half a year to sequence the SARS coronavirus after the outbreak began in late 2002.

How long will it take?
Lam noted that although candidate vaccines may be available in a matter of weeks, it would take much longer for them to be evaluated for human use.
“These candidate vaccines have to be tested in animal studies before human clinical trials can be started. It is still a long road ahead, and by the time a vaccine is ready, the outbreak may already be over — like in the case of SARS, where it took 20 months before a candidate vaccine was developed,” said Lam.
The vaccine never made it to the market because the virus was successfully contained with public health measures. The vaccine against MERS, meanwhile, is still being developed.
Immunologist Datuk Dr Musa Nordin said despite the pressure to come up with a vaccine as soon as possible, it must be noted that vaccine development remains an expensive and risky process.
“On average, it takes 10 years from pre-clinical trials through Phase 1-3 clinical trials before it is proven efficacious and safe for registration by regulatory bodies and use in man.
“However, the Covid-19 has the benefit of experience with previous candidate vaccines for MERS and SARS, allowing a jump start on the development of vaccines. If I had to hazard a best optimistic guess, I would say (a Covid-19 vaccine would be developed) within six months,” he said to Bernama.

What if it mutates?
One of the fears is that the Covid-19 would mutate after a vaccine is finally developed, affecting its efficacy.
However, it should be noted that Covid-19 does not undergo the same type of genome shuffling as the influenza virus, which is constantly mutating.
Like SARS, the genome of the Covid-19 comprises a single strand of RNA (ribonucleic acid). Microbes with such genome are known to mutate very quickly, but SARS has a molecular proofreading system that reduces its mutation rate.
Given the similarity to SARS at the genomic level, it has been suggested that the Covid-19 would not be as prone to mutation as the flu virus, which comprises multiple single-stranded RNA segments.
Therefore, if a vaccine is produced, it would still be effective.
Lam said that mutation is always a possibility with RNA viruses like the Covid-19.
“Usually, a major change happens when the virus jumps species. Hopefully, if there is a mutation, it will be a minor and not involving the spike protein, which is the important antigen used to produce the neutralising antibody in our immune system.
“With minor changes, the vaccine will still offer protection, or modify the severity of the disease,” he said.
CEPI
The Coalition of Endemic Preparedness Innovations (CEPI) in January announced that it would be funding three programmes to develop vaccines against the 2019-nCov.
It has engaged, among others, the Queensland University to work on a vaccine using its recently developed rapid response technology.
The university’s head of School of Chemistry and Molecular Biosciences Prof Paul Young said that they would be using the novel technology, known as the molecular clamp, for the rapid generation of the vaccine.
Young’s team of researchers have already experienced using this novel technology to produce candidate vaccines against influenza, Nipah, Ebola, and MERS. The team is optimistic that it will be able to develop the Covid-19 vaccine within six months.
“We are working around the clock to produce enough of the spike proteins in cells to produce this sub-unit vaccine,” said Young in an email.
A sub-unit vaccine is a fragment of a pathogen, typically a surface protein that is used to trigger an immune response. This in turn will stimulate acquired immunity against the pathogen from which it is derived.
CEPI is a non-profit organisation formed in 2017 to fund vaccine development for emerging infectious diseases. It is based in Oslo, Norway, and is a global partnership created to spearhead development

Genting Singapore takes a hit from Wuhan virus outbreak, but the tables could soon turn
SINGAPORE (Feb 11): Genting Singapore (GENS) appears to be one of the companies badly hit by the outbreak of the novel coronavirus (2019-nCoV). Since Jan 20, the counter has plunged 9.5%.
Market watchers opine that the city state’s gaming industry is one of the sectors that could bear the brunt of the virus due to its high dependency on foreign tourist arrivals, including tourists from mainland China.
As of Feb 11, Singapore has 45 confirmed cases, making it the country with the second most number of infected patients outside of China. It had also recently raised its Disease Outbreak Response System Condition (DORSCON) level to Orange in a bid to contain the outbreak.

State-owned Perak Corp now a PN17 firm
KUALA LUMPUR (Feb 11): Perak Corp Bhd — whose Movie Animation Park Studios (MAPS) theme park in Ipoh was closed last month until further notice — has lapsed into Practice Note 17 (PN17) status.
The state-owned firm told the stock exchange today that it is now regarded a PN17 company, arising from the default in payment and its inability to declare solvency.
This comes after the group defaulted on another repayment of principal, this time in respect of the Musharakah Mutanaqisah Term Financing-i and Tawarruq Revolving Credit-i of up to RM100 million granted by Affin Islamic Bank Bhd.
Last October, Animation Theme Park Sdn Bhd — a 51%-owned subsidiary of PCB Development Sdn Bhd, which in turn is a wholly-owned unit of Perak Corp — defaulted in its repayment of principal for a syndicated term loan facility of up to RM280 million involving Affin Hwang Investment Bank Bhd, Affin Bank Bhd, Bank Pembangunan Malaysia Bhd and Malaysia Debt Ventures Bhd.
“After taking into consideration the group’s current cash flow position vis-à-vis its total debt obligations payable and the available cash flow, the company is unable to declare that it is solvent, pursuant to paragraph 9.19A(4) of the Listing Requirements.
“Arising from the default in payment and the company is unable to declare that it is solvent, the company has triggered the prescribed criteria under paragraph 2.1(f) of the PN 17 of the Listing Requirements,” it added.

Sumatec misses deadline to submit quarterly report, share trade suspension continues
KUALA LUMPUR (Dec 3): Sumatec Resources Bhd has missed the deadline to submit its quarterly report for the financial period ended Sept 30, 2019 (3QFY19).
In a bourse filing today, Sumatec said in the event it is unable to submit its 3QFY19 report on or before Dec 6, trading in its securities will be suspended from 9am on Monday, Dec 9.
However, Sumatec said as its securities have been suspended from trading since Nov 7 following a winding up order against the company, the suspension of trading will continue until further notice.
Sumatec slipped into PN17 status in April 2018 when its external auditors Messrs Grant Thornton Malaysia expressed a disclaimer of opinion on the company's audited financial statements for the financial year ended Dec 31, 2017.
The group received a petition last August from its bondholders demanding payment of RM83.31 million from three collateralised loans they had extended to Sumatec.
Under Bursa Malaysia Securities' Main Listing Requirements, if a listed issuer fails to issue the outstanding financial statements within six months from the expiry of the relevant timeframes, in addition to any enforcement action that Bursa Securities may take, delisting procedures shall be commenced against such listed issuer.

ARUL KANDA A/L KANDASAMY 18,000,500 shares

10 Dec 2019 RAJA DATO' HAJI IDRIS RAJA KAMARUDIN Disposed 150,000
9 Dec 2019 RAJA DATO' HAJI IDRIS RAJA KAMARUDIN Disposed 220,400
25 Nov 2019 TDM RAJA DATO' HAJI IDRIS RAJA KAMARUDIN Disposed 100,000
21 Nov 2019 TDM RAJA DATO' HAJI IDRIS RAJA KAMARUDIN Disposed 50,000
18 Nov 2019 TDM RAJA DATO' HAJI IDRIS RAJA KAMARUDIN Disposed 50,000
12 Nov 2019 TDM RAJA DATO' HAJI IDRIS RAJA KAMARUDIN Disposed 150,000

EKOVEST BHD
Notice of Person Ceasing (Section 139 of CA 2016)

Name : EMPLOYEES PROVIDENT FUND BOARD
Country of Incorporation : Malaysia

Circumstances by reason of which change has occurred:
Disposed

2014 CHEONG CHIA CHIEH have 62% PUC stakes he selling reduces to 40% in 2015. In Feb 2016 CHEONG CHIA CHIEH Age 44 died from hemophagocytic lymphohistiocytosis .ESTATE OF THE LATE CHEONG CHIA CHIEH eldest brother CHEONG CHIA CHOU takeover manages operating PUC.
2018 CHEONG CHIA CHOU takeover brother 40% he start selling reduces to 10% reason is CHEONG CHIA CHOU now Age 45 he feel not well in last year .hemophagocytic lymphohistiocytosis is Genetic disease It's not easy to live to 40s is miracle .PUC no family successor so need to reduces to simple controlling stakes like non current asset company shares holding exchange to cash for both family and selling to other people takeover PUC.

11 Dec 2019 CHEONG CHIA CHOU Disposed 10,000,000 shares 6.37%
CHEONG CHIA CHOU want.....

9 Dec 2019 CHEONG CHIA CHOU Disposed 19,618,100 shares reduced to 6.7970%

5 Dec 2019 CHEONG CHIA CHOU Disposed 64,279,800 shares reduced to 7.62%

7 Nov 2019 CHEONG CHIA CHOU Disposed 63,913,043 shares 10.48%

21 Oct 2019 CHEONG CHIA CHOU Disposed 60,000,000 shares 13.71%

11 Oct 2019 CHEONG CHIA CHOU Disposed 60,000,000 shares 16.54%

22 Jul 2019 CHEONG CHIA CHOU Disposed 25,000,000 shares 19.88%

12 Jun 2019 CHEONG CHIA CHOU Disposed 21,427,000 shares 21.04%

20 Mar 2019 CHEONG CHIA CHOU Disposed 55,000,000 shares 22.03%

18 Mar 2019 CHEONG CHIA CHOU Disposed 55,000,000 shares 24.58%

4 Jan 2019 CHEONG CHIA CHOU Disposed 60,000,000 shares 25.53%

2018 CHEONG CHIA CHOU takeover brother 40% he start selling reduces to 10% reason is CHEONG CHIA CHOU now Age 45 he feel not well in last year .hemophagocytic lymphohistiocytosis is Genetic disease It's not easy to live to 40s is miracle .PUC no family successor so need to reduces to simple controlling stakes like non current asset company shares holding exchange to cash for both family and waiting other people takeover PUC.

https://klse.i3investor.com/blogs/tombthieves/217720.jsp

The Board of ARB (“Board”) wishes to announce that ARB Development Sdn Bhd, a wholly-owned subsidiary of the Company, and East Insurance had on 9 December 2019 mutually agreed to terminate the MOU with immediate effect (“Termination”).
The MOU termination will not have any material effect on the Company and its subsidiaries.
Further details of the MOU are set out in the attachment below.
This announcement is dated 9 December 2019.

2018 CHEONG CHIA CHOU takeover brother 40% he start selling reduces to 10% reason is CHEONG CHIA CHOU now Age 45 he feel not well in last year .hemophagocytic lymphohistiocytosis is Genetic disease It's not easy to live to 40s is miracle .PUC no family successor so need to reduces to simple controlling stakes like non current asset company shares holding exchange to cash for both family and waiting other people takeover PUC.

CHEONG CHIA CHOU all private own tech company sell to PUC.
CHEONG CHIA CHOU from 10% PUC selling reduces to 7.62%.
later PUC sell to other boss .